Details

Autor(en) / Beteiligte

• Sakai, Mari
• Miyazaki, Yasushi
• Matsuo, Emi
• Moriuchi, Yukiyoshi
• Hata, Tomoko
• Fukushima, Takuya
• Imaizumi, Yoshitaka
• Imanishi, Daisuke
• Taguchi, Jun
• Iwanaga, Masako
• Tsushima, Hideki
• Inoue, Yoriko
• Takasaki, Yumi
• Tsuchiya, Takeshi
• Komoda, Minori
• Ando, Koji
• Horio, Kensuke
• Moriwaki, Yuji
• Tominaga, Shinya
• Itonaga, Hidehiro
• Nagai, Kazuhiro
• Tsukasaki, Kunihiro
• Tsutsumi, Chizuko
• Sawayama, Yasushi
• Yamasaki, Reishi
• Ogawa, Daisuke
• Kawaguchi, Yasuhisa
• Ikeda, Shuichi
• Yoshida, Shinichiro
• Onimaru, Yasuyuki
• Tawara, Masayuki
• Atogami, Sunao
• Koida, Satoshi
• Joh, Tatsuro
• Yamamura, Masaomi
• Matsuo, Yuji
• Soda, Hisashi
• Nonaka, Hiroaki
• Jinnai, Itsuro
• Kuriyama, Kazutaka
• Tomonaga, Masao

Titel

Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group

Ist Teil von

• International journal of hematology, 2009-04, Vol.89 (3), p.319-325

Ort / Verlag

Tokyo: Springer Japan

Erscheinungsjahr

2009

Quelle

MEDLINE

Beschreibungen/Notizen

• Imatinib has dramatically improved long-term survival of chronic myelogenous leukemia (CML) patients. To analyze its efficacy in a practical setting, we registered most of CML patients in Nagasaki Prefecture of Japan. Of these, 73 patients received imatinib as an initial therapy. The overall survival rate of these patients was 88.7% at 6 years, and the cumulative complete cytogenetic response rate was 82.5% at 18 months. These results are comparable with the data of other reports including the IRIS study; however, the administered imatinib dose was smaller in our study than that in other reports. To address these discrepancies, we measured the trough concentration of imatinib among 35 patients. Although 39% of the patients were administered less than 400 mg/day, the trough level was comparable to those of previous reports. The trough level of imatinib showed a significant relationship with its efficacy, and was clearly related to dose of imatinib administrated and dose of imatinib divided by body surface area (BSA). Considering the smaller BSA of Japanese patients as compared to those of foreign origin, the results suggest that a lower dose of imatinib could maintain enough trough level and provided excellent results for the treatment of CML in our registry.